ICER Extends Influence Among US Insurers With AHIP Subscription Deal
AHIP arrangement is a big win for ICER and will facilitate access to the organization’s cloud-based cost effectiveness review platform for a broad range of payers, particularly small and mid-size companies that may not have the resources to subscribe to the service on their own.
You may also be interested in...
Arnold Ventures: How A Philanthropy Helped Tip The Scales In US Drug Pricing Debate
A review of grants by the organization to a range of recipients engaged in work on lowering drug prices.
Manufacturer Engagement In ICER Reviews Widespread; How Much It Helps Is Less Clear
Tufts study evaluates the extent and impact of manufacturer engagement with the Institute for Clinical and Economic Review while recent survey by Xcenda finds payer reliance on ICER reports is growing.
US Advanced Purchases For COVID Drugs A Model Post-Pandemic? Not Likely, Manufacturers Warn
Drug developers discuss transitioning the pricing and purchasing of their COVID treatments to the private market during an advisory panel meeting hosted by the Institute for Clinical and Economic Review.